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Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically 
worldwide and, subsequently, also the risk of developing non-alcoholic steatohepatitis 
(NASH), hepatic fibrosis, cirrhosis and cancer. Today, weight loss is the only available 
treatment, but administration of fibroblast growth factor 21 (FGF21) analogues have, 
in addition to weight loss, shown improvements on liver metabolic health but the 
mechanisms behind are not entirely clear. The aim of this study was to investigate the 
hepatic metabolic profile in response to FGF21 treatment. Diet-induced obese (DIO) 
mice were treated with s.c. administration of FGF21 or subjected to caloric restriction by 
switching from high fat diet (HFD) to chow to induce 20% weight loss and changes were 
compared to vehicle dosed DIO mice. Cumulative caloric intake was reduced by chow, 
while no differences were observed between FGF21 and vehicle dosed mice. The body 
weight loss in both treatment groups was associated with reduced body fat mass and 
hepatic triglycerides (TG), while hepatic cholesterol was slightly decreased by chow. Liver 
glycogen was decreased by FGF21 and increased by chow. The hepatic gene expression 
profiles suggest that FGF21 increased uptake of fatty acids and lipoproteins, channeled 
TGs toward the production of cholesterol and bile acid, reduced lipogenesis and increased 
hepatic glucose output. Furthermore, FGF21 appeared to reduce inflammation and 
regulate hepatic leptin receptor-a expression. In conclusion, FGF21 affected several 
metabolic pathways to reduce hepatic steatosis and improve hepatic health and markedly 
more genes than diet restriction (61 vs 16 out of 89 investigated genes).
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most 
common liver disorder in the Western world (1, 2) with a 
global prevalence of 25% (3). It is defined as steatosis (fat 
accumulation) in at least 5% of hepatocytes (3). Obesity 
is a central risk factor for developing NAFLD (4), and it is 
estimated that 39% of all adults worldwide are overweight 
and 13% are obese (5). NASH is a further deterioration 
from the steatosis characteristic of NAFLD accompanied 
by inflammation and hepatocyte damage. Prevalence of 
NASH estimates among NAFLD patients range from 25 
to 59% (3, 4). Liver fibrosis stage is the most important 
determinant of long-term outcome for NAFLD patients 
(6), and approximately 20% of NASH patients develop 
liver cirrhosis (4). Cirrhosis is the second most common 
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cause of liver transplantation in the US (3), and patients 
with cirrhosis have an increased risk of developing liver 
cancer (4).
Currently, no pharmaceutical treatment for NASH 
is approved, but many compounds targeting various 
pathways are in the clinical pipeline, as reviewed by 
Rotman & Sanyal (7). Presently, the most effective 
method to alleviate NASH is body weight loss (4, 8), but 
to reverse fibrosis a body weight loss of at least 10% needs 
to be achieved (9). Fibroblast growth factor 21 (FGF21) is 
a hormone expressed primarily by the liver and adipose 
tissue. Treatment with FGF21 induces weight loss in 
rodents, non-human primates and early clinical trials (10, 
11, 12). In diet-induced obese (DIO) mice, FGF21 lowers 
body weight by increasing energy expenditure (EE), 
whereas body weight loss in pigs (13) and in some non-
human primates appears to be driven by a decrease in food 
intake (10). FGF21 treatment has multiple effects on the 
liver either by direct or indirect actions (11). For instance, 
FGF21 has been shown to reduce hepatic steatosis 
through increased fatty acid (FA) oxidation and decreased 
lipogenesis in rodents (11). Moreover, an FGF21 analogue 
has been shown to reduce inflammation and fibrogenesis 
in a NASH mouse model using leptin-deficient ob/ob mice 
and a methionine- and choline-deficient (MCD) diet (14). 
Likewise, in a phase 2 trial, a protracted FGF21 reduced 
liver fat, liver injury and fibrosis biomarkers in NASH 
patients (15). In addition to hepatic lipid regulation, 
FGF21 treatment also improved glycemic control in 
DIO mice (11, 16). However, this effect did not seem to 
translate as convincingly to humans (10, 12), while an 
increase in insulin sensitivity has been observed (17). 
Improved hepatic leptin signaling and leptin sensitivity 
have also been suggested to contribute to the effects by 
FGF21, as the leptin receptor (Lepr) expression was highly 
induced in DIO mice treated with FGF21 (11, 18). Leptin 
is an adipose-derived hormone, which plays an important 
role in control of appetite and energy homeostasis (19). 
LEBRB is considered to be the functional receptor for 
leptin’s effect on energy balance mainly through central 
regulation, while the effects of the shorter isoforms of the 
leptin receptor (isoform a, c, d and f) are largely unresolved 
(20). However, they have been suggested to function as 
leptin binding proteins (11, 21, 22, 23, 24, 25).
To obtain a broader mechanistic understanding of 
FGF21 in the liver, we aimed to provide a comprehensive 
analysis of simultaneous regulation of multiple hepatic 
metabolic pathways to drive new hypothesis and studies. 
In DIO mice, a 20% body weight loss was induced by 
FGF21 treatment or by caloric restriction (achieved by 
switching from high fat diet (HFD) to chow) for 18 days. 
Gene expression analysis in liver tissue was conducted 
by high-throughput qPCR investigating 89 genes within 
glucose- and lipid metabolism, inflammation and 
leptin signaling.
Materials and methods
Animals
Animals were used in compliance with internationally 
accepted principles for the care and use of laboratory 
animals and were approved by the internal Novo Nordisk 
Ethical Review Committee in Denmark. The study was 
conducted according to approved national regulations 
in Denmark. It was performed at Novo Nordisk, China, 
and was conducted under licenses granted by the Beijing 
Administration Office of Laboratory Animals (BAOLA). 
Animals were obtained from Jackson Laboratories and 
were housed and maintained in standard, temperature- 
and humidity-controlled environment and were subject to 
a 12 h light:12 h darkness cycle (lights on at 06:00 h). The 
animals had access to water and food ad libitum. During 
the treatment phase of the study, the mice were given 
either regular chow (no. 1324, Altromin, Brogaarden, 
Lynge, Denmark) or HFD (Research Diet #D12492, 
New Brunswick, NJ, USA).
Study design
Thirty male C57BL/6J DIO mice (approximately 20 weeks 
of age; 3.0 g) were put on a 60% kcal fat diet from 4 to 
5 weeks of age. The mice were single-housed and 
acclimated to handling for 13 days prior to the start 
of treatment. Body weight (BW) and food intake were 
measured daily around 07:00 h by manual weighing. A 
magnetic resonance scan (Echo MRI) was conducted 6 
days before study start, and mice were distributed into 
three groups such that statistical variations in BW, fat mass 
and fat/BW% were minimized between groups. At study 
start, the mice had a mean BW of 46.8 ± 3.0 g. All mice 
were dosed subcutaneously twice daily with either vehicle 
or native FGF21 (Novo Nordisk A/S, 0.6 mg/kg/day) for 
18 days. The selected dose for FGF21 was based on internal 
data to obtain 20% body weight loss. Control and FGF21 
treated mice were maintained on HFD, while mice in the 
diet restricted group were switched to standard chow 
ad libitum (~11% kcal fat). At day 18, without prior fasting, 
animals were subjected to a second MR scan (2 h after 
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last dosing) and were killed by cervical dislocation under 
anesthesia by isoflurane inhalation (7 h after last dosing). 
Blood was sampled during anesthesia from the retro-
orbital vein into EDTA-coated tubes, centrifuged (6000 g 
at 4°C for 5 min), and plasma isolated and stored at −80°C 
until analysis. Liver tissues were collected immediately, 
snap-frozen in liquid nitrogen and stored at −80°C.
Plasma and tissue analysis
Plasma leptin and insulin were measured by luminescent 
oxygen channeling (LOCI) assays (Perkin Elmer alphaLISA, 
kit AL521F). Frozen liver samples of 20–42 mg were used 
for the determination of lipid and glycogen as previously 
described (26). Note that, in this study, samples were 
homogenized with Tissuelyser II (Qiagen) at 30 Hz for 
2× 45 s and analyzed on Cobas 6000 Analyzer (Roche 
Diagnostics). True TG was calculated as TG subtracted 
glycerol and glycogen as total glucose subtracted the free 
glucose. Due to the limited amount of tissue, the number 
of samples in each group was as follows: control = 9, 
chow = 10, and FGF21 = 8.
RNA purification
RNA extraction from frozen liver samples (10–30 mg) was 
conducted according to RNeasy Lipid Tissue Handbook 
2009 (Qiagen), protocol ‘Purification of Total RNA Using 
the RNeasy Lipid Tissue Mini Kit’, with some modifications. 
TRIzolR Reagent (Invitrogen) was used for cell lysis, 
and homogenization was performed using Tissuelyser 
II (Qiagen) for 2× 2 min at 20 Hz. Phase separation was 
conducted with 1-Bromo-3-chloropropane (Sigma Life 
Science). DNase treatment was done on-columns after 
step 10, according to Appendix C of the protocol. RNA 
concentration was measured by NanoDrop-1000 (Thermo 
Scientific) and purity accessed from OD260/280. Integrity was 
tested on Agilent 2100 Bioanalyzer (Agilent Technologies) 
using the RNA 6000 Nano Kit. Samples with an RNA 
Integrity Number (RIN) ≥ 5 were used for downstream 
analysis (control: n = 10, OD260/280 = 2.0 ± 0.1, RIN = 7.8 ± 1.0; 
chow: n = 9, OD260/280 = 2.0 ± 0.0, RIN = 7.4 ± 1.2; FGF21: 
n = 7, OD260/280 = 2.1 ± 0.0, RIN = 5.9 ± 0.6. Values are 
mean ± s.d.).
cDNA synthesis
For each RNA sample two cDNA replicates were made 
separately from 1000 ng RNA using iScript™ cDNA 
Synthesis Kit (Bio-Rad), containing a blend of oligo(dT) 
and random hexamer primers, in a final reaction volume 
of 20 µL according to the manufacturer’s protocol. A 
negative control was made for each group by omitting RT 
in the reaction. Following manufacturer’s instructions, 
the reactions were incubated 5 min at 25°C, 30 min at 
42°C and 5 min at 85°C. The cDNA was stored at −80°C 
until use.
Primer design
Selection of the genes of interest in the liver was focused on 
lipid and carbohydrate metabolic pathways, inflammation 
and leptin signaling and based on available RNA-
sequencing data from in-house studies (Novo Nordisk A/S), 
on the presumption of differential gene expression between 
the groups. Gapdh, Ywhaz and Sdha were tested as reference 
genes, as they have been reported to be stably expressed in 
similar studies (27, 28, 29). Initially, 96 genes were selected. 
Primer sequences were obtained from the database 
PrimerBank (30) or designed using Primer-BLAST (https://
www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were 
selected to flank an intron and make amplicons in the range 
of 75–200 nucleotides when possible and to have a narrow 
melting temperature between 60 and 63°C. Primers were 
purchased from Sigma-Aldrich. The sequences are listed 
in Supplementary Table 1 (see section on supplementary 
materials given at the end of this article).
High-throughput qPCR
High-throughput qPCR was conducted with the Biomark 
HD system (Fluidigm) on a 96.96 IFC chip. cDNA 
samples were pre-amplified with a pool of all assays to 
be analyzed. Fifteen PCR cycles of 5× diluted cDNA 
using TaqMan PreAmp Master Mix (Life Technologies) 
followed by Exonuclease I (New England BioLabs) 
cleanup was performed according to the manufacturer’s 
protocol (Fluidigm PN100-5875C1), apart from using 
primer concentrations of 250 nM. Samples were further 
5× diluted and qPCR reactions were conducted using 2× 
SsoFast™ EvaGreen® Supermix with Low ROX (Bio-Rad 
Laboratories) according to manufacturer’s instructions 
(Fluidigm PN100-9792B1), except from final primer 
concentrations of 5 µM. A RT control from each group 
was included and standard curves were made from a 
cDNA pool of equal amounts of all pre-amplified and 
exonuclease treated samples. The thermal cycling profile 
used was GE 96.96 Fast PCR+Melt v2.pcl with melting 
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curve analysis. Data were collected with Biomark HD Data 
Collection software.
qPCR data analysis
The efficiency for each assay was calculated from the 
log-linear portion of the standard curve and assays with 
efficiencies from 85 to 115% and R2 ≥ 0.98 were accepted. 
Data were analyzed in GenEx6 Pro (MultiD Analyses 
AB). Quantification cycle (Cq) values were corrected to 
assay efficiency and the reference genes were tested by 
the normalization algorithms GeNorm and Normfinder. 
Gapdh and Ywhaz were used for normalization, Cq values 
of cDNA replicates were averaged and fold changes (FC) 
were obtained by setting the expression of the treatment 
groups relative to the control group.
Follow-up by conventional qPCR
Two failed assays (Srebf1, Leprb) and three additional ones 
(Lepra, Lepr, Hmgcl) were subsequently analyzed using 
conventional qPCR on MX3005P (Agilent). For each 10 µL 
reaction, 1 µL 5× diluted cDNA, 5 µL 2× QuantiFast™ 
SYBR Green master mix (Qiagen) and 1 µM primer were 
mixed. Standard curves were made based on a cDNA pool 
of all samples in the study. Leprb was too low expressed to 
provide reliable analysis. Data were analyzed in GenEx6 
Pro as described previously, apart from normalization to 
Gapdh, which was the most stable reference gene observed. 
The thermal profile was 95°C for 5 min, 40 cycles of 95°C 
for 10 s and 60°C for 30 s, ending with melting curve 
analysis (60–99°C). Data were collected using MxPro 
QPCR Software version 4.10.
Statistical analysis
Leptin and insulin plasma levels were log10 transformed 
and FCs log2 transformed to obtain normal distribution 
of residuals. One-way ANOVA followed by Tukey’s post 
hoc test was performed using either GenEx6 Pro or the 
statistical software R version 3.2.3. Unless otherwise 
stated, qPCR data are presented as mean treatment 
FC relative to the control group while other data are 
presented as means ± s.e.m. Since genes were specifically 
selected on the presumption of differential expression, 
multiple comparison analysis was not performed, and 
P < 0.05 was considered statistically significant. Graphs, 
figures and tables were created in Microsoft Excel and 
Microsoft PowerPoint.
Results
FGF21 reduced body weight to the same extent as 
switching diet from HFD to chow
In the FGF21 (0.6 mg/kg daily dosing) treated DIO mice, 
the caloric restriction induced by chow resulted in similar 
BW loss (Fig. 1A, chow 18.0% ± 1.2%, FGF21 21.3% ± 0.8%) 
and ~10.5% body fat mass reduction after 18 days (Fig. 
1C, chow 10.5% ± 1.2%, FGF21 10.5% ± 1.4%). The 
cumulative caloric intake was reduced by chow, while 
no difference was observed between the FGF21-treated 
and control mice (Fig. 1B, control 244.4 ± 8.9 kcal, chow 
172.0 ± 8.8 kcal, FGF21 239.3 ± 8.8 kcal).
Plasma insulin and leptin
Plasma leptin and insulin were reduced to similar 
degree in mice treated with FGF21 and chow compared 
to the control group (Fig. 1D, control 70.1 ± 7.1 ng/mL, 
chow 11.5 ± 2.5 ng/mL, FGF21 16.2 ± 2.2 ng/mL; Fig. 1E, 
control 626.5 ± 192.0 pM, chow 191.1 ± 48.5 pM, FGF21 
232.5 ± 65.0 pM).
Hepatic lipid and glycogen content
The hepatic triglyceride (TG) content was decreased to a 
similar degree by FGF21 and chow (Fig. 1F, control 
136.5 ± 15.1 µM/g, chow 50.1 ± 9.2 µM/g, FGF21 
35.0 ± 5.0 µM/g), while cholesterol was reduced by chow 
(Fig. 1G, control 9.9 ± 0.3 µM/g, chow 8.3 ± 0.3 µM/g, 
FGF21 9.3 ± 0.4 µM/g) compared to control mice. 
Glycogen content was decreased by FGF21 and increased 
by chow compared to control mice (Fig. 1H, control 
253.5 ± 19.3 µM/g, chow 331.3 ± 15.2 µM/g, FGF21 
173.3 ± 27.2 µM/g).
Hepatic gene expression
Of the 89 genes investigated in the liver, 70 showed 
significant differential regulation (Supplementary Table 2). 
The genes which are presented in the result section have 
focus on the impact of FGF21. Overall, treatment with FGF21 
affected significant more genes than mice shifted diet from 
HFD to chow compared to vehicle-treated mice on HFD.
Regulation of transcription factors governing 
energy balance
Peroxisome proliferator-activated receptor alpha (Ppara), 
an important transcription factor (TF) inducing FA 
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oxidation, was upregulated by FGF21 while slightly 
downregulated by chow (Table 1). FGF21 also upregulated 
the expression of peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (Ppargc1a, PGC-1a), 
a transcriptional coactivator that increases FA oxidation, 
gluconeogenesis and mitochondrial biosynthesis, 
and NAD-dependent protein deacetylase sirtuin-1 (Sirt1), 
an enzyme required for PGC-1a induction of gluconeogenic 
genes. Forkhead box protein A2 (Foxa2) and hepatocyte 
nuclear factor 4-alpha (Hnf4a) were both induced by 
FGF21 treatment but not by chow. Foxa2 is a central 
regulator of glucose, lipid and bile acid (BA) homeostasis 
(31, 32), while Hnf4a is another essential metabolic TF 
that induces gluconeogenesis (33) and BA metabolism (34, 
35). Conversely, the farnesoid X receptor (Fxr) inhibitor of 
BA synthesis (36) was also upregulated by FGF21. Sterol 
regulatory element-binding protein 1 (Srebf1), encoding 
central activators of lipogenesis, cholesterol synthesis 
and uptake (37), as well as the glucose-induced lipogenic 
TF, carbohydrate-responsive element-binding protein 
(ChREBP, Mlxipl) (38), were upregulated by FGF21. Finally, 
the adipogenic TF peroxisome proliferator-activated 
receptor gamma (Pparg) was downregulated by FGF21.
Regulation of genes modulating 
carbohydrate metabolism
Genes downstream from the transcriptional regulators 
modulated by FGF21 generally changed expression 
profiles in the same direction as the corresponding TF. 
Glycogen phosphorylase (Pygl) was upregulated by FGF21 
(Table 2), consistent with upregulation of the glucagon 
receptor (Gcgr) and reduced hepatic glycogen (Fig. 1H). 
Mitochondrial pyruvate carrier 2 (Mpc2), mediating 
Figure 1
The effect of 18 days treatment of diet restriction 
(chow) and FGF21 in DIO mice. (A) Percentage of 
body weight loss, (B) the cumulative food intake 
(kcal), (C) percentage of body fat loss, (D) plasma 
leptin levels, (E) plasma insulin levels, (F) hepatic 
triglyceride levels, (G) hepatic cholesterol levels, 
and (H) hepatic glycogen level. Data are means ± 
s.e.m., with n = 8–10 in each group. ‘1’ indicates 
significant differences to the vehicle, ‘2’ significant 
differences to chow, and ‘3’ significant differences 
to FGF21 (*P < 0.05, **P < 0.01, ***P < 0.001). 
Statistical analyses were performed using 
one-way ANOVA with Tukey’s post hoc test. Group 
size, n = 10.
Table 1 Hepatic mRNA expression of transcriptional 
regulators involved in metabolism in DIO mice treated with 
diet restriction (chow) or FGF21 for 18 days.
Transcript
Chow vs 
control
FGF21 vs 
control
FGF21 vs 
chow
Foxa2 1.4 3.0c 2.1a
Fxr 1.1 1.9c 1.7c
Hnf4a 1.1 2.4c 2.2c
Mlxipl 1.5 5.3c 3.5b
Ppara −1.2a 1.6c 1.9c
Pparg −1.2 −3.5c −3.0c
Ppargc1a 1.1 2.1c 2.0c
Sirt1 1.2 2.1c 1.8c
Srebf1 1.3 2.2c 1.7a
Values represent fold changes with ‘−’ indicating downregulation. Foxa2, 
Forkhead box protein A2; Fxr, farnesoid X receptor; Hnf4a, hepatocyte 
nuclear factor 4-alpha; Mlxipl, carbohydrate-responsive element-binding 
protein; Ppara, peroxisome proliferator-activated receptor alpha; Pparg, 
peroxisome proliferator-activated receptor gamma; Ppargc1a, peroxisome 
proliferator-activated receptor gamma co-activator 1a; Sirt1, sirtuin-1; 
Srebf1, sterol regulatory element-binding protein 1. Srebf1 was 
investigatied by conventional qPCR.
aP < 0.05; bP < 0.01; cP < 0.001. Statistical analyses were performed using 
one-way ANOVA with Tukey's post hoc test. Group size, n = 10.
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pyruvate uptake into mitochondria, and pyruvate 
dehydrogenase E1 component subunit b (Pdhb), part 
of the pyruvate dehydrogenase complex (PDC), were 
both downregulated by FGF21. On the other hand, an 
inhibitor of the PDC, pyruvate dehydrogenase kinase 
isozyme 4 (Pdk4), was downregulated. The gluconeogenic 
phosphoenolpyruvate carboxykinase (Pepck) was 
upregulated (also in accordance with upregulated Gcgr), 
together with glucose 6-phosphatase 3 (G6pc3) and glucose 
transporter type 2 (Glut2). The glycolytic glucokinase 
(Gck) was also upregulated by FGF21, though to a lesser 
extent than G6pc3 (Fig. 2 and Table 2). FGF21 treatment 
also induced the expression of the insulin-sensitizing 
adiponectin receptor protein 2 (Adipor2) and the insulin 
receptor (Insr) compared to control and chow, while chow 
had significantly induced Insr compared to control (Fig. 4).
Regulation of genes modulating lipid metabolism
FGF21 treatment regulated more genes than chow 
(Table 3). Chow induced the lipogenic fatty acid 
synthase (Fasn) and elongation of very long-chain fatty 
acids protein 3 (Elovl3), while the lipolytic lipoprotein 
lipase (Lpl) was downregulated. Fatty acid translocase 
(Cd36), facilitating uptake of oxidized low-density 
lipoprotein (oxLDL) and long-chain fatty acids (39), 
was downregulated. Microsomal triglyceride transfer 
protein (Mttp), controlling the rate-limiting process for 
very low-density lipoprotein (VLDL) secretion from the 
liver (38), was slightly upregulated. Finally, mice shifted 
to chow diet had increased expression levels of the rate-
controlling enzyme of cholesterol biosynthesis, HMG-CoA 
reductase (Hmgcr) and the enzyme (cystein sulfinic acid 
decarboxylase (Csad)), catalyzing the synthesis of taurine, 
a component of bile salt. FGF21 treatment increased 
gene expression of LDL receptor (Ldlr) and high-density 
lipoprotein (HDL) receptor, scavenger receptor class B 
member 1 (Scarb1), the collective action of which would 
improve cholesterol clearance. On the other hand, the 
LDLR degrading proprotein convertase subtilisin/kexin 
type 9 (Pcsk9) was also upregulated by FGF21. The two 
lipogenic genes, stearoyl-CoA desaturase 1 (Scd1) and 
Elovl3, were markedly downregulated by FGF21 treatment, 
while, on the contrary, acetyl CoA carboxylase 1 (Acaca) 
was slightly upregulated. The FA oxidative carnitine 
palmitoyltransferase 1a (Cpt1a) was increased, and so 
was hepatic triacylglycerol lipase (Lipc) and adipose 
triglyceride lipase (Atgl), mediating degradation of TG 
from lipoproteins and lipid droplets (40). Also contributing 
to the hepatic FA pool was upregulation of fatty acid 
transport protein 2 (Fatp2). Cd36 was downregulated 
similar to chow, while Mttp was upregulated to a higher 
degree by FGF21. Decreased expression of the ketogenic 
HMG-CoA lyase (Hmgcl), together with increased 
expression of Hmgcr, and markedly downregulation of the 
HMGCR-inhibitor insulin-induced gene 2 (Insig2), suggest 
that the acetyl-CoA obtained from FA oxidation was 
used for cholesterol biosynthesis. Cholesterol 7-alpha-
monooxygenase (Cyp7a1), mediating the rate-limiting 
step in BA synthesis, was upregulated, together with 
sterol 12-alpha-hydroxylase (Cyp8b1) and the cholesterol 
transporters Sterolin-1 (Abcg5) and sterolin-2 (Abcg8) 
(Fig. 2 and Table 3).
Regulation of Fgf21, Klb and Fgfrs
The mRNA expression of Fgf21 was significantly reduced 
by chow and FGF21 treatment, whereas FGF21 induced 
the expression of FGF receptor family Fgfr2 and Fgfr4 and 
Klb (Fig. 3).
Regulation of leptin receptors
The functional isoform of the leptin receptor, Leprb, 
showed very low mRNA expression both on the Fluidigm 
Table 2 Hepatic mRNA expression of genes involved in 
glucose metabolism in DIO mice treated with diet restriction 
(chow) or FGF21 for 18 days.
Transcript
Chow vs 
control
FGF21 vs 
control
FGF21 vs 
chow
Cox7a1 −1.1 −1.5a −1.3
G6pc3 −1.0 2.7c 2.8c
Gcgr −1.1 2.1c 2.3c
Gck −1.1 1.4a 1.6b
Glut2 1.1 1.5a 1.3
Gys2 −1.2 1.1 1.3a
Mpc2 −1.1 −2.4b −2.2a
Pdhb −1.1 −1.6b −1.4a
Pdk4 1.0 −1.6 −1.7
Pepck 1.2 1.9b 1.6a
Pklr 1.1 1.1 1.0
Pygl 1.4 2.6c 1.8a
Uqcrh −1.0 −1.6a −1.5
Usmg5 −1.0 −1.7a −1.7a
Values represent fold changes with ‘−’ indicating downregulation. Cox7a1, 
Cytochrome c oxidase subunit 7a1; G6pc3, glucose 6-phosphatase 3; Gcgr, 
glucagon receptor; Gck, glucokinase; Glut2, glucose transporter type 2; 
Gys2, glycogen synthase; Mpc2, mitochondrial pyruvate carrier 2; Pdhb, 
pyruvate dehydrogenase E1 component subunit beta; Pdk4, pyruvate 
dehydrogenase kinase isozyme 4; Pepck, phosphoenolpyruvate 
carboxykinase; Pklr, pyruvate kinase; Pygl, glycogen phosphorylase liver; 
Uqcrh, cytochrome b-c1 complex subunit 6; Usmg5, upregulated during 
skeletal muscle growth 5.
aP < 0.05; bP < 0.01; cP < 0.001. Statistical analyses were performed using 
one-way ANOVA with Tukey’s post hoc test. Group size, n = 10.
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platform and with conventional qPCR. Therefore, an 
assay targeting all leptin receptor transcript variants 
(Lepr) and one measuring only the short a-variant (Lepra) 
were run, both showing 2.9-fold upregulation by FGF21. 
Signal transducer and activator of transcription 3 (Stat3), 
a TF activated by LEPRB signaling, was not significantly 
regulated by the treatments, while inhibitors of leptin 
signalling, Socs3 and Ptp1b, were upregulated, primarily 
by FGF21 (Fig. 4).
Regulation of genes involved in inflammation and 
oxidative stress
Expression of the proinflammatory cytokine interleukin 
18 (Il18) was 3.5-fold downregulated by FGF21, but not 
by chow, whereas another biomarker of inflammation, 
lipocalin 2 (Lcn2), was about five-fold downregulated by 
both treatments. The hepatokine fetuin-A (Ahsg), which 
mediates FA activation of toll-like receptor 4 (TLR4) (41), 
was induced by FGF21. Inhibitor of κB kinase epsilon 
(Ikbke), which recently was revealed to limit the chronic 
nature of inflammation (42), was 3.8-fold upregulated by 
FGF21 treatment. Mitochondrial uncoupling protein 2 
(Ucp2), which reduces the generation of reactive oxidative 
species (ROS) (43), was upregulated by FGF21 compared 
to chow, while the endoplasmic reticulum (ER) chaperone 
78-kDa glucose-regulated protein (Hspa5), a key regulator 
of protective responses to the accumulation of misfolded 
proteins, was upregulated by FGF21 compared to both 
chow and control (Fig. 5). Interleukin 1b (Il1b), macrophage 
migration inhibitory factor (Mif) and carbonyl reductase 
1 (Cbr1) were not significantly regulated (Supplementary 
Table 2).
Discussion
In the present study, comparable (~20%) body weight loss 
was induced by FGF21 and by shifting diet from HFD to 
chow in DIO mice at day 18. Similar degree of BW loss 
allows the investigation of BW-independent actions of 
FGF21. The body weight loss was associated with reduction 
in body fat mass, liver fat, plasma leptin and insulin. For 
mice treated with FGF21, weight loss was independent of 
caloric intake, indicating an increase in EE as the primary 
driver for efficacy (11). To understand the effect of FGF21 
in the liver, we investigated simultaneous regulation of 
multiple hepatic metabolic pathways. The presented gene 
Figure 2
Illustration of the hepatic mRNA expression of genes involved in glucose and lipid metabolism at day 18 in DIO mice treated with FGF21. Values in green 
and red colors represent significant (P < 0.05) fold changes in FGF21-treated mice compared to the control group. Green (↑) indicates upregulation by 
FGF21 and red (↓) means downregulation. G1P, Glucose 1-phosphate; G6P, glucose 6-phosphate; PEP, phosphoenolpyruvate; FA, fatty acid; TG, 
triglyceride. For gene names, see Tables 1–3. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test. Group size, n = 10.
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expression profile demonstrated that the FGF21 treatment 
affected markedly more hepatic genes than mice shifted 
from HFD to chow (61 vs 16 out of 89). For the mice 
shifted from HFD to chow diet, the most regulated genes 
were found in the lipid metabolism related to reduced fat 
and cholesterol in the diet (44). We are aware that shifting 
from HFD to chow diet without including lean control 
mice makes it difficult to discuss whether the chow 
mice in the present study have normalized their gene 
regulation due to diet or weight loss. However, Siersbaek 
and colleagues have demonstrated a reversed hepatic 
gene expressing profile when changing from HFD to a 
chow diet, supporting normalization of the gene 
regulation profile by chow (44).
Within the hepatic carbohydrate metabolism, the 
gene expression profile suggested that FGF21 induce 
hepatic glucose mobilization. This was indicated by (1) 
upregulation of the several transcript factors (Ppargc1a, 
Foxa2, Hnf4a), (2), upregulation of genes in the 
gluconeogenesis (Pepck, G6pc3) and the glycogenolysis 
(Gcgr, Pygl), (3) reduced hepatic glycogen content 
and (4) downregulation of genes converting pyruvate 
into acetyl-CoA production (Pdhb, Mpc2) (Fig. 2 and 
Table 1). In addition, the increase in Glut2 expression 
by FGF21 suggested greater capacity for hepatic glucose 
flux. However, there are contradicting results showing a 
dose-dependent downregulation of G6pc3 by FGF21 in 
DIO mice while no effect on Pepck, suggesting a reduced 
hepatic glucose production derived from glycogenolysis 
(16). Coskun and colleagues showed a decreased Pepck 
expression indicating a decreased gluconeogenesis (11). 
In the present study, the three-fold upregulation of Foxa2, 
a TF for Pepck and G6pc3, together with the increased 
expression of Pygl and low hepatic glycogen levels highly 
suggest increased glycogenolysis and gluconeogenesis. 
Increased gluconeogenesis has previously been reported 
with FGF21 indicated by increased Foxa2 (11), PGC-1a 
(Ppargc1a) (45) and reduced PDC (46), supporting the 
present study result that FGF21 may induce hepatic 
glucose mobilization. The potentially enhanced hepatic 
Figure 3
Hepatic mRNA expression of Fgf21 and Fgf receptors in DIO mice treated 
with diet restriction (chow) or FGF21. Fgf21, fibroblast growth factor 21; 
Klb, klotho-beta receptor subunit; Fgfr2, fibroblast growth factor receptor 
2; Fgfr4, fibroblast growth factor receptor 4. ‘1’ indicates significant 
differences to the vehicle, ‘2’ significant differences to chow, and ‘3’ 
significant differences to FGF21 (*P < 0.05, **P < 0.01, ***P < 0.001). 
Statistical analyses were performed using one-way ANOVA with Tukey’s 
post hoc test. Group size, n = 10.
Table 3 Hepatic mRNA expression of genes involved in lipid 
metabolism in DIO mice treated with diet restriction (chow) or 
FGF21 for 18 days.
Transcript
Chow vs 
control
FGF21 vs 
control
FGF21 vs 
chow
Abcg5 1.1 2.6c 2.3c
Abcg8 1.4 2.5b 1.9a
Acaca 1.3 1.6b 1.2
Atgl 1.3 2.0c 1.6b
Cd36 −1.9a −2.1b −1.1
Cpt1a −1.1 2.2c 2.5c
Csad 2.9b 1.6 −1.8
Cyp7a1 1.6 3.9c 2.4b
Cyp8b1 1.4 2.5c 1.7b
Dgat2 −1.1 1.3 1.4b
Elovl3 1.8a −3.6c −6.5c
Fasn 1.9a 1.6 −1.1
Fatp2 1.1 2.2c 2.0c
Gpam 1.0 1.3 1.2
Hmgcl −1.4 −2.c −1.5a
Hmgcr 1.7a 3.8c 2.2b
Insig2 −1.2 −5.8c −5.0c
Ldlr 1.1 3.1c 2.8c
Lipc 1.3 2.4c 1.7b
Lpl −1.5a 1.3 1.9c
Mttp 1.3a 2.2c 1.7c
Pcsk9 1.2 3.3c 2.7c
Scarb1 1.1 3.4c 3.2c
Scd1 1.7 −5.3c −9.3c
Values represent fold changes with ‘−’ indicating downregulation. Abcg5, 
Sterolin-1; Abcg8, sterolin-2; Acaca, acetyl-CoA carboxylase 1; Atgl, adipose 
triglyceride lipase; Cd36, fatty acid translocase; Cpt1a, carnitine 
palmitoyltransferase 1a; Csad, cystein sulfinic acid decarboxylase; Cyp7a1, 
cholesterol 7-alpha-monooxygenase; Cyp8b1, sterol 12-alpha-hydroxylase; 
Dgat2, diacylglycerol O-acyltransferase 2; Elovl3, elongation of very 
long-chain fatty acids protein 3; Fasn, fatty acid synthase; Fatp2, fatty acid 
transport protein 2; Gpam, glycerol-3-phosphate acyltransferase; Hmgcl, 
HMG-CoA lyase; Hmgcr, HMG-CoA reductase; Insig2, insulin-induced gene 
2; Ldlr, low-density lipoprotein receptor; Lipc, hepatic triacylglycerol lipase; 
Lpl, lipoprotein lipase; Mttp, microsomal triglyceride transfer protein; 
Pcsk9, proprotein convertase subtilisin/kexin type 9; Scarb1, scavenger 
receptor class B member 1; Scd1, stearoyl-CoA desaturase 1. Hmgcl was 
measured by conventional qPCR.
aP < 0.05; bP < 0.01; cP < 0.001. Statistical analyses were performed using 
one-way ANOVA with Tukey’s post hoc test. Group size, n = 10.
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glucose production is, however, not associated with 
increased blood glucose levels as FGF21 lowers blood 
glucose in other studies (11, 47). The enhanced hepatic 
glucose production may supply the brown adipose tissue 
(BAT) with fuel, secondary to increases in EE expenditure 
(48, 49). Villarroya and colleagues have previously 
demonstrated that FGF21 stimulate the glucose uptake 
in BAT and specifically induce the glucose oxidative 
activity (48). FGF21 has, moreover, been revealed to 
induce conversion of adipocytes from white adipose 
tissue to brown fat-like cells and increased the expression 
of thermogenic genes (49, 50). Thus, FGF21 may induce 
weight loss in DIO mice by directing glucose away from 
the liver toward BAT for heat production and increased 
energy expenditure.
Genes involved in hepatic lipid metabolism were 
also highly regulated by FGF21 compared to mice shifted 
to chow diet. The expression pattern induced by FGF21 
suggests that hepatic TG was channeled toward the 
synthesis of acetyl-CoA, since lipolytic and FA oxidative 
genes were upregulated (Fig. 2). An exception to this 
pattern was the upregulation of the lipogenic Acaca 
which together with absent regulation of the FA oxidation 
inhibitor Acacb disagrees with previous publications 
(11, 16), and we do not have an explanation for this. 
However, Atgl was induced with two-fold upregulation 
which may be important for FGF21 to reduce hepatic 
steatosis, in part, by mobilizing FA from lipid droplets. 
ATGL has recently been reported as a major hepatic lipase; 
knockdown of Atgl in the liver of mice induced steatosis 
and overexpression of Atgl is associated with increased 
FA oxidation (51). Furthermore, downregulation of the 
ketogenic Hmgcl and upregulation of the rate-controlling 
enzyme in cholesterol synthesis Hmgcr suggest that the 
synthesized acetyl-CoA was channeled toward cholesterol 
production. These pathways were further supported 
by upregulation of cholesterol exporters and enzymes 
working in the synthesis of BAs pointing toward increased 
production of bile (Fig. 2). Previous, it has been shown 
that Abcg5 and Abcg8 were downregulated by hepatic 
overexpression of FGF21 (52), but this was measured 
in an acute study and may, therefore, differ from the 
present chronic study. On the other hand, overexpression 
of hepatic FGF21 and increased hepatic expression of 
Cyp7a1, Abcg5 and Abcg8 has likewise been shown in 
DIO mice associated with increased BA pool collected 
from liver, gallbladder, and small intestine and increased 
the fecal BA content (52). Unfortunately, neither BA nor 
cholesterol content in feces was measured in the present 
study, but Coskun et al. reported a 30% increase in fecal 
fat in mice treated with FGF21 (11). Thus, it may seem 
likely that increased cholesterol synthesis and subsequent 
catabolism (via synthesis of BAs and export into bile) may 
Figure 5
Hepatic mRNA expression of inflammatory and anti-oxidative stress-
related genes at day 18 in DIO mice treated with diet restriction (chow) or 
FGF21. Il18, interleukin 18; Lcn2, lipocalin-2; Ahsg, fetuin-A; Ikbke, 
inhibitor of nuclear kappa-B kinase subunit epsilon; Ucp2, mitochondrial 
uncoupling protein 2; Hspa5, 78-kDa glucose-regulated protein. ‘1’ 
indicates significant differences to the vehicle, ‘2’ significant differences to 
chow, and ‘3’ significant differences to FGF21 (*P < 0.05, **P < 0.01,  
***P < 0.001). Statistical analyses were performed using one-way ANOVA 
with Tukey’s post hoc test. Group size, n = 10.
Figure 4
Hepatic mRNA expression of different receptors and related genes at day 
18 in diet-induced obese (DIO) mice treated with diet restriction (chow) or 
FGF21. Lepr, leptin receptor all variants; Lepra, leptin receptor a; Insr, 
insulin receptor; Adipor2, adipornectin receptor 2; Stat3, signal transducer 
and activator of transcription 3; Socs3, suppressor of cytokine signaling-3; 
Ptp1b, tyrosine-protein phosphatase non-receptor type 1. Lepr and Lepra 
were measured by conventional qPCR. ‘1’ indicates significant differences 
to the vehicle, ‘2’ significant differences to chow, and ‘3’ significant 
differences to FGF21 (*P < 0.05, **P < 0.01, ***P < 0.001). Statistical 
analyses were performed using one-way ANOVA with Tukey’s post hoc 
test. Group size, n = 10.
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be contributing factors in the beneficial effects of FGF21 
on steatosis. Particularly, the 5.8-fold reduced expression 
of Insig2 may be a central mechanism, as INSIG proteins 
act in a feedback mechanism to reduce the synthesis and 
uptake of cholesterol when endogenous levels are high 
(37). The role of INSIGs is to inhibit HMGCR expression, 
and reduced Insig2 expression will thereby circumvent the 
natural downregulation of cholesterol synthesis. Apart 
from being a way of dispatching energy via feces, BAs 
are increasingly being recognized as metabolic regulatory 
molecules. Stimulation of the BA receptor TGR5 increases 
EE in BAT as well as GLP-1 secretion in the intestinal 
L-cells (53). Also, in gastric bypass patients, increased 
BA has been suggested to contribute to the improved 
metabolic profile (54, 55). Thus, induction of cholesterol 
and bile metabolism may likely be important for FGF21 in 
the liver, but further investigations are needed.
SOCS3 and PTPB1 negative regulate several 
intracellular metabolic pathways such as growth hormone 
(GH) (56, 57), insulin (58, 59, 60), and leptin (20) 
signalling pathways. In the present study, the induction 
of Socs3 and Ptp1b may be mediated through adiponectin 
(25) as the Adipor2 was induced by FGF21 (61). Reduced 
GH response fits well with the reduced expression levels 
of Ghr and Igf (Supplementary Table 2) and has previously 
been found with FGF21 (56, 57). On the contrary, the 
increased hepatic Insr expression and reduced plasma 
insulin suggest increased hepatic insulin sensitivity (62). 
Within the liver, INSR stimulates lipogenesis and inhibits 
gluconeogenesis, but this was not evident in the present 
study despite upregulation of Insr. Thus, the increase 
in Insr may then be secondary to a dramatic decrease 
in plasma insulin which also was observed by chow. In 
addition, Emanuelli and colleagues showed that intact 
hepatic insulin signaling is required for most of the action 
of FGF21 on lipid metabolism (49). The LIRKO mice 
and FGF21 treated mice have overlapping phenotypes, 
indicating that hepatic lipid regulation by FGF21 is 
mediated by lack of insulin.
The leptin receptor transcripts and downstream 
signaling pathway were also investigated to determine 
hepatic leptin signaling, as leptin is important in body 
weight regulation through binding to LEPRB (20). In 
addition, the hepatic Lepr has been shown to be markedly 
increased by FGF21 in DIO mice and suggested to be 
associated with enhanced leptin signaling and sensitivity 
mice (11, 18). Within the liver, there is no clear evidence 
of leptin’s role, but it has been suggested to act as a 
profibrotic molecule by direct activation of LEPRB on 
hepatic stellate cells (25). In the present study, the Leprb 
was expressed at too low levels to be analyzed, which may 
be associated with the upregulation of Socs3 and Ptpb1 
(63), respectively. This finding suggests that LEPRB was 
not a part of the hepatic improvement induced by FGF21. 
On the other hand, FGF21 induced same significant 
enhanced expression of all leptin transcript variants (Lepr) 
and the specific transcript Lepra that mimic the increased 
leptin receptor expression demonstrated by Coskun and 
colleagues (11, 18). Hepatic LEPRA is suggested to regulate 
leptin bioavailability via cleavage from the membrane to 
a soluble leptin receptor (SLR) (21, 64). Unfortunately, 
no data on SLR were available in the present study, 
but in-house data showed that FGF21 induce SLR dose 
dependently in plasma.
Obesity is characterized by a state of chronic low-
grade inflammation, which is an important causative 
factor behind associated metabolic diseases (65). FGF21, 
but not chow, reduced the expression of the inflammatory 
cytokine Il18. To be active, pro-Il18 needs cleavage by 
the NLRP3 inflammasome that is central in metabolic 
triggered inflammation (65) and fibrosis development 
in the steatotic liver (66, 67). IKBKE negatively regulates 
the NLRP3 inflammasome (42), and the 3.8-fold induced 
expression of Ikbke seen by FGF21 in the present study, 
while not by chow, could then indicate that FGF21 protects 
against inflammatory processes induced by HFD. Oxidized 
low-density lipoproteins (oxLDLs) are also implicated in 
the inflammatory and fibrotic process in NASH through 
binding to the CD36 receptor (39). oxLDL is formed 
from LDL in response to oxidative stress (ROS), and the 
level of circulating LDL seems to be proportional to the 
amount of oxLDL (39). In the present study, the reduced 
expression of Cd36 together with increased expression of 
Ucp2 and Hspa5 (reduce oxidative stress), and increased 
expression of Ldlr (increase the hepatic clearance of LDL) 
by FGF21 may be protective mechanisms against hepatic 
inflammatory processes. In addition, increased expression 
of Adipor2 and reduced expression of Mpc2 by FGF21 and 
not by chow also support that FGF21 independent of 
weight loss protected the liver against inflammation and 
inflammatory processes (25, 68, 69, 70).
An important question is whether the findings in the 
DIO mice can be translated into humans. Weight loss 
observed in the DIO mice does not appear to correlate 
well in humans as only limited weight loss has been 
demonstrated in humans (10, 12). On the other hand, 
the pronounced effect of FGF21 in lowering hepatic fat 
have been observed in both DIO mice (11) and humans 
(10, 15, 71), indicating a more promising translation from 
the DIO mice to humans. Recently, Akero demonstrated 
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impressive reduction in hepatic fat with a Fc conjugated 
FGF21 analogue in humans with a BMI > 25. The relative 
hepatic fat content was reduced to 70% after 12 weeks 
of treatment and was not driven by weight loss (71). 
Thus, the effect was driven by other mechanisms. In 
mice, it cannot be distinguished whether the increase in 
energy expenditure and/or weight loss have contributed 
to the reduction in hepatic fat. However, a lowering of 
plasma insulin has been observed in both the DIO mice 
and humans (12). This could indicate that insulin may 
contribute to the anti-steatotic effect through decreased 
hepatic lipogenesis and increased oxidation in both 
DIO mice and humans. In our study, the hepatic gene 
expression profile indicates a clear decrease in lipogenesis 
and increased lipid oxidation and may likely correspond 
to humans. Furthermore, the improved hepatic 
inflammatory response that appears observed in the 
DIO mice may also translate well into humans, as NASH 
patients treated with a protracted FGF21 analogue were 
protected against hepatic inflammation (15).
Another central question is whether the hepatic 
improvements by FGF21 are related directly or indirectly. 
The literature is controversial as direct signaling in 
hepatocytes in vitro (72) and liver in vivo (73) are observed, 
while the liver-specific KLB KO display unaltered FGF21 
sensitivity (74). The direct effect on liver may depend on 
the pharmacological dose (72, 75), as FGF21 binds with 
higher affinity toward the FGFR1c/KLB complex compared 
to the FGFR3c/KLB complex (76). FGFR1c is not expressed 
by the liver, but FGF21 may mediate its hepatic effect 
through FGFR3c/KLB signaling (76, 77, 78). In the present 
study, Fgfr2, Fgfr4 and Klb were all upregulated by FGF21, 
suggesting a need for increased hepatic FGF signaling. 
FGF15’s suppressing effect on bile acids metabolism s 
dependent on FGFR4 and KLB expression in hepatocytes 
(77). The upregulation of Fgfr4 may be an endogenous 
compensatory mechanism to increase the binding sites 
for FGF15. However, as BA synthesis is increased due to 
upregulation of CYP7A1, a decrease in FGF15 activity is 
anticipated. Therefore, FGF21 may decrease inhibition of 
BA synthesis by antagonizing the effect of FGF15, which 
has also been reported previously in mice (79).
In conclusion, administration of FGF21 reduced 
BW and hepatic steatosis independent of caloric intake 
in DIO mice. In the present study, a panel of hepatic 
genes important for the multiple metabolic pathways 
was investigated to provide a broader mechanistic 
understanding of FGF21 and to drive new hypothesis 
and studies. We showed that FGF21 affected several 
metabolic pathways to reduce hepatic steatosis and to 
drive anti-inflammatory and anti-fibrogenic properties. 
The hepatic gene expression profile suggested that 
FGF21 increased uptake of fatty acids and lipoproteins, 
channeled TGs toward the production of cholesterol and 
bile acid, reduced lipogenesis and increased the secretion 
of VLDLc and glucose output. The increased hepatic 
BA synthesis and glucose mobilization do also suggest 
that FGF21 provide substrates derived from the liver for 
increasing EE. The increase of BA may likely be involved 
in the induction of EE through TGR5 activation where 
the glucose mobilization may be used as an energy source 
in BAT. This study was done in mice with high metabolic 
rate, which need to be taken into consideration when 
mode of actions of FGF21 are discussed in humans.
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